OBJECTIVE: Treatment with anthracyclines may cause cardiac dysfunction, but the sequence of anthracycline-induced heart lesions has been incompletely characterized. NADPH oxidase, a key mediator of oxidative cardiac damage and remodeling, modulates anthracycline clinical cardiotoxicity. Our aim was to determine which cardiac histological lesions are specifically induced by anthracycline treatment and to investigate the role of NADPH functional genetic polymorphisms in their development. PATIENTS AND METHODS: Using a retrospective case-control design, we evaluated cardiac histological lesions and NADPH genotype (polymorphisms rs1883112, rs4673, and rs13058338) in 97 consecutive decedents with a cancer diagnosis (48 treated with anthracyclines). RESULTS: Myocytolysis (60%), patched myocardial necrosis (19%), and myocardial fibrosis (diffuse and patched; 62% and 23%, respectively) were associated with anthracycline treatment. In patients receiving anthracyclines, NADPH oxidase polymorphism rs4673 protected against focal myocardial necrosis (odds ratio [OR], 0.11; 95% confidence interval [CI], 0.20-0.63) whereas rs1883112 was strongly associated with cardiac fibrosis (OR, 5.11; 95% CI, 1.59-16.43), which was present in all homozygotes. CONCLUSION: Anthracyclines induce a cardiac remodeling pattern characterized by interstitial or patched fibrosis. The contribution of the functionally relevant NADPH polymorphisms rs1883112 and rs4673 to anthracycline-related heart lesions provides a plausible explanation for their modulation of cardiotoxicity. If confirmed, these findings may lead to better individualized strategies for early detection and prevention of anthracycline cardiotoxicity.
OBJECTIVE: Treatment with anthracyclines may cause cardiac dysfunction, but the sequence of anthracycline-induced heart lesions has been incompletely characterized. NADPH oxidase, a key mediator of oxidative cardiac damage and remodeling, modulates anthracycline clinical cardiotoxicity. Our aim was to determine which cardiac histological lesions are specifically induced by anthracycline treatment and to investigate the role of NADPH functional genetic polymorphisms in their development. PATIENTS AND METHODS: Using a retrospective case-control design, we evaluated cardiac histological lesions and NADPH genotype (polymorphisms rs1883112, rs4673, and rs13058338) in 97 consecutive decedents with a cancer diagnosis (48 treated with anthracyclines). RESULTS: Myocytolysis (60%), patched myocardial necrosis (19%), and myocardial fibrosis (diffuse and patched; 62% and 23%, respectively) were associated with anthracycline treatment. In patients receiving anthracyclines, NADPH oxidase polymorphism rs4673 protected against focal myocardial necrosis (odds ratio [OR], 0.11; 95% confidence interval [CI], 0.20-0.63) whereas rs1883112 was strongly associated with cardiac fibrosis (OR, 5.11; 95% CI, 1.59-16.43), which was present in all homozygotes. CONCLUSION:Anthracyclines induce a cardiac remodeling pattern characterized by interstitial or patched fibrosis. The contribution of the functionally relevant NADPH polymorphisms rs1883112 and rs4673 to anthracycline-related heart lesions provides a plausible explanation for their modulation of cardiotoxicity. If confirmed, these findings may lead to better individualized strategies for early detection and prevention of anthracyclinecardiotoxicity.
Authors: M S Ewer; M K Ali; B Mackay; S Wallace; M Valdivieso; S S Legha; R S Benjamin; T P Haynie Journal: J Clin Oncol Date: 1984-02 Impact factor: 44.544
Authors: Leszek Wojnowski; Bettina Kulle; Markus Schirmer; Gregor Schlüter; Albrecht Schmidt; Albert Rosenberger; Stefan Vonhof; Heike Bickeböller; Mohammad Reza Toliat; Eun-Kyung Suk; Mladen Tzvetkov; Anke Kruger; Silvia Seifert; Marita Kloess; Heidi Hahn; Markus Loeffler; Peter Nürnberg; Michael Pfreundschuh; Lorenz Trümper; Jürgen Brockmöller; Gerd Hasenfuss Journal: Circulation Date: 2005-12-05 Impact factor: 29.690
Authors: John J Doyle; Alfred I Neugut; Judith S Jacobson; Victor R Grann; Dawn L Hershman Journal: J Clin Oncol Date: 2005-12-01 Impact factor: 44.544
Authors: J E Megías-Vericat; P Montesinos; M J Herrero; F Moscardó; V Bosó; L Rojas; D Martínez-Cuadrón; R Rodríguez-Veiga; L Sendra; J Cervera; J L Poveda; M Á Sanz; S F Aliño Journal: Pharmacogenomics J Date: 2017-05-09 Impact factor: 3.550
Authors: Folefac Aminkeng; Colin J D Ross; Shahrad R Rassekh; Soomi Hwang; Michael J Rieder; Amit P Bhavsar; Anne Smith; Shubhayan Sanatani; Karen A Gelmon; Daniel Bernstein; Michael R Hayden; Ursula Amstutz; Bruce C Carleton Journal: Br J Clin Pharmacol Date: 2016-06-30 Impact factor: 4.335
Authors: Daniel J Serie; Julia E Crook; Brian M Necela; Travis J Dockter; Xue Wang; Yan W Asmann; DeLisa Fairweather; Katelyn A Bruno; Gerardo Colon-Otero; Edith A Perez; E Aubrey Thompson; Nadine Norton Journal: Pharmacogenet Genomics Date: 2017-10 Impact factor: 2.089